教員業績データベース |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis. |
掲載誌名 | 正式名:European journal of gastroenterology & hepatology ISSNコード:14735687/0954691X |
掲載区分 | 国外 |
巻・号・頁 | 34,pp.698-706 |
著者・共著者 | Tada, Toshifumia; Kumada, Takashib; Hiraoka, Atsushic; Hirooka, Masashid; Kariyama, Kazuyae; Tani, Jojif; Atsukawa, Masanorig; Takaguchi, Koichih; Itobayashi, Eii; Fukunishi, Shinyaj; Tsuji, Kunihikok; Ishikawa, Torul; Tajiri, Kazutom; Ochi, Hironorin; Yasuda, Satoshio; Toyoda, Hidenorio; Ogawa, Chikarap; Nishimura, Takashi; Hatanaka, Takeshir; Kakizaki, Satorus; Shimada, Noritomot; Kawata, Kazuhitou; Tanaka, Takaakic; Ohama, Hidekoj; Nouso, Kazuhiroe; Morishita, Asahirof; Tsutsui, Akemih; Nagano, Takuyah; Itokawa, Noriog; Okubo, Tomomig; Arai, Taeangg; Imai, Michitakal; Naganuma, Atsushiv; Koizumi, Yoheid; Nakamura, Shinichiroa; Joko, Koujin; Iijima, Hiroko Hiasa, Yoichid; On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group |
発行年月 | 2022/06 |